Ablynx amps up expectations for rare disease drug; Boehringer nears EU nod for IPF contender;

@FierceBiotech: EuroBiotech Report: U.K. starts ambitious drug dev review, Onxeo to raise €41.6M, Galapagos mulls Nasdaq listing. More | Follow @FierceBiotech

@JohnCFierce: 5 of the top 10 biotech news stories of the year so far in FierceBiotech are on immuno-oncology. Oh, my. | Follow @JohnCFierce

@DamianFierce: $ABBV's hep C combo will be branded as Viekirax + Exviera (at least in Europe). More from the EMA | Follow @DamianFierce

> Allergy specialist Stallergenes has licensed a preclinical candidate from partner ActoGeniX, promising up to €75 million ($93 million) in milestones. News

> Belgium's Ablynx is dialing up its sales expectations for caplacizumab, a rare disease treatment, now saying the drug could bring in nearly $500 million a year if approved. Story

> Boehringer Ingelheim is inching closer to competing with IPF rival Roche ($RHHBY) in Europe, as the continental drug regulator has recommended approval for Ofev, the German drugmaker's treatment for the lung-scarring disease. Item

Medical Device News

@FierceMedDev: InfoBionic gets $17M to offer cloud-based cardiac monitoring. Story | Follow @FierceMedDev

@StacyALawrence: Second Sight IPO pops 122% in first day. That's 8th largest IPO pop this year in any sector. See my updated story. | Follow @StacyALawrence

@VarunSaxena2: Smith & Nephew closes U.S. facility, sells another in U.K. with 100+ to be laid off $SNN. More | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FierceDiagnostics: Illumina and bioMérieux to develop innovative sequencing system for infectious diseases. Article | Follow @EmilyWFierce

> Gates Foundation backs Ebola trials for plasma-based and other treatments. Article

> Tandem partners for open-source software to improve insulin pump data access. More

> Boston Scientific ordered to hand over $18.5M in vaginal mesh litigation. Story

Pharma News

@FiercePharma: #FDA approves Purdue's abuse-resistant Hysingla, a hydrocodone pill aimed at knocking off Zohydro. Story | Follow @FiercePharma

@CarlyHFierce: #ICYMI yesterday - Themis, Institut Pasteur expand collaboration on solid PhI Chikungunya results. | Follow @CarlyHFierce

> Boehringer one step closer to challenging Roche in Europe with EMA IPF nod. Story

> Merck's Zetia results inflame debate over statin prescribing. More

> Sanofi nears European Gaucher market shakeup with EMA rec. Story

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.